IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA

免疫学和基于免疫的治疗议程

• 批准号: 5205506
• 负责人: ROBERT T SCHOOLEY
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5205506
• 关键词: AIDS; AIDS related neoplasm /cancer; AIDS therapy; HIV infections; antineoplastics; biomarker; cellular immunity; clinical research; communicable disease control; cooperative study; cytokine; human immunodeficiency virus 1; human subject; human therapy evaluation; humoral immunity; immunization; immunomodulators; immunotherapy; neoplasm /cancer immunotherapy; opportunistic infections; oxidative stress; pathologic process; virus load; virus replication

Toxoplasma gondii encephalitis occurs in up to 30% of HIV-infected individuals with latent infection. Anti-toxoplasma chemotherapy is often toxic, and despite adequate therapy, disease recurs in up to 50% of patients with AIDS. An understanding of the cellular immune response to T. gondii infection may aid in the development of improved predictors of the risk for recrudescent disease, and may lead to effective immunotherapies. We have constructed recombinant vaccinia viruses that express the 28-kD toxoplasma antigen. A second vector that expresses the p22 antigen of T. gondii is currently being constructed in our laboratory. By using these vectors to induce autologous EBV-transformed lymphoblasts to express toxoplasma antigens, we can examine cytotoxic T-cell activity of cells derived from individuals with a history of T. gondii infection. We propose to study toxoplasma-specific CTL responses of T. gondii-seropositive, HIV- infected individuals.

多达30％的HIV感染 患有潜在感染的人。 抗氧化学疗法通常是 有毒，尽管有足够的治疗，但疾病还是在多达50％的 艾滋病患者。 对细胞免疫反应的理解。 Gondii感染可能有助于发展改进的预测因子 出现重新疾病的风险，并可能导致有效的免疫疗法。 我们已经构建了表达28 kd的重组疫苗病毒 弓形虫抗原。 表达T的p22抗原的第二个载体。 Gondii目前正在我们的实验室建造。 通过使用这些 向量诱导自体EBV转换的淋巴细胞表达 弓形虫抗原，我们可以检查细胞的细胞毒性T细胞活性 源自具有T. gondii感染史的个体。 我们建议 研究弓形虫 - 垂直阳性，HIV- 受感染的人。